...
首页> 外文期刊>Vox Sanguinis: International Journal of Blood Transfusion and Immunohaematology >The impact of a medium molecular weight, low molar substitution hydroxyethyl starch dissolved in a physiologically balanced electrolyte solution on blood coagulation and platelet function in vitro.
【24h】

The impact of a medium molecular weight, low molar substitution hydroxyethyl starch dissolved in a physiologically balanced electrolyte solution on blood coagulation and platelet function in vitro.

机译:溶解在生理平衡的电解质溶液中的中等分子量,低​​摩尔取代度的羟乙基淀粉对体外凝血和血小板功能的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and Objectives Hydroxyethyl starches (HES) may have the potential to impact negatively on haemostasis. Recent findings suggest that side-effects on haemostasis stem not only from the physicochemical differences between HES, but also from the composition of the solvent. We compared the effects of a newly developed medium molecular weight (MW) and low molar substitution (MS) HES dissolved in a physiologically balanced electrolyte solution (MW 130, MS 0.42; B-HES) with a commercially available non-balanced HES (MW 130, MS 0.4; NB-HES), and with Ringer's lactate (RL) solution in vitro. Materials and Methods Activated partial thromboplastin time (APTT), factor VIII clotting activity (F VIII:C) and von Willebrand factor (vWF) activity were investigated in 48 healthy individuals. Platelet function as measured by turbidimetric platelet aggregometry and whole blood impedance aggregometry induced by adenosine diphosphate (ADP), collagen and thrombin receptor activating peptide (TRAP), and by ADP and TRAP-induced expression of activated platelet fibrinogen receptor glycoprotein (GP) IIb/IIIa was determined in 24 participants. Haemodilution (25% and 50%, v/v for blood coagulation analyses and 20% and 40%, v/v for platelet function studies) was performed using the two HES preparations and RL. Results APTT was significantly longer and F VIII and vWF significantly lower at 25% and 50% dilutions with NB-HES compared to B-HES and RL. At 20% and 40% dilutions, ADP and TRAP-induced expression of activated platelet surface GP IIb/IIIa was significantly increased by B-HES compared to NB-HES and RL. Percentages of platelet GP IIb/IIIa expression were also significantly greater in samples diluted with B-HES than in undiluted blood. Neither the diluent (B-HES, NB-HES and RL) nor the degree of dilution (undiluted, 20% and 40% dilution) had any significant influence on ADP, collagen or TRAP-induced turbidimetric platelet aggregation or impedance platelet aggregation. Conclusions In contrast to a non-balanced 130 kDa, MS0.4 HES (NB-HES), a 130 kDa, MS 0.42 HES preparation dissolved in a physiologically balanced electrolyte solution (B-HES) does not affect APTT, F VIII:C and vWF in vitro. Both types of HES do not affect platelet aggregation induced by ADP, collagen or TRAP. B-HES but not NB-HES increases the expression of activated platelet GP IIb/IIIa induced by ADP or TRAP.
机译:背景与目的羟乙基淀粉(HES)可能会对止血产生负面影响。最近的发现表明止血的副作用不仅源于HES之间的理化差异,还源于溶剂的组成。我们将溶解在生理平衡的电解质溶液(MW 130,MS 0.42; B-HES)中的新开发的中等分子量(MW)和低摩尔取代度(MS)HES与市售非平衡HES(MW)进行了比较130,MS 0.4; NB-HES)和林格氏乳酸(RL)溶液体外。材料和方法在48位健康个体中研究了活化的部分凝血活酶时间(APTT),凝血因子VIII凝血活性(F VIII:C)和血管性血友病因子(vWF)活性。通过比浊血小板凝集法和全血阻抗凝集法测量血小板功能,该方法由二磷酸腺苷(ADP),胶原蛋白和凝血酶受体激活肽(TRAP)以及ADP和TRAP诱导的活化血小板纤维蛋白原受体糖蛋白(GP)IIb /的表达来测量IIIa是在24位参与者中确定的。使用这两种HES制剂和RL进行了血液稀释(25%和50%,v / v用于凝血分析,20%和40%,v / v用于血小板功能研究)。结果与B-HES和RL相比,NB-HES分别稀释25%和50%时,APTT显着更长,F VIII和vWF显着降低。与NB-HES和RL相比,B-HES在20%和40%的稀释度下,ADP和TRAP诱导的活化血小板表面GP IIb / IIIa的表达显着增加。用B-HES稀释的样品中的血小板GP IIb / IIIa表达百分比也显着高于未稀释的血液。稀释剂(B-HES,NB-HES和RL)或稀释度(未稀释,20%和40%稀释)均对ADP,胶原蛋白或TRAP诱导的比浊血小板凝集或阻抗血小板凝集没有任何显着影响。结论与非平衡130 kDa MS0.4 HES(NB-HES)相比,溶于生理平衡电解质溶液(B-HES)的130 kDa MS 0.42 HES制剂不影响APTT,F VIII:C和体外vWF。两种类型的HES均不影响ADP,胶原蛋白或TRAP诱导的血小板聚集。 B-HES而非NB-HES会增加ADP或TRAP诱导的活化血小板GP IIb / IIIa的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号